Table 2.
Distribution of eight respiratory viruses according to the age groups patients with acute respiratory infections
| Age group (OR a , 95% Cl) | |||||||
|---|---|---|---|---|---|---|---|
| <1 | l‐5 b | 6‐19 | 20‐49 | 50‐64 | >65 | ||
| (n = 2,386) | (n = 14,456) | (n = 7,274) | (n = 7,084) | (n = 3,665) | (n = 2,050) | Total | |
| HAdV | 192 | 2.013 | 376 | 136 | 39 | 8 | 2,764 |
| (1.09, 0.93‐1.27) | (4.67, 4.28‐5.09) | (0.62, 0.56‐0.70) | (0.20, 0.17‐0.24) | (0.12, 0.09‐0.17) | (0.05, 0.02‐0.09) | ||
| HPIVs | 237 | 1.285 | 223 | 178 | 137 | 65 | 2,125 |
| (1.90, 1.65‐2.19) | (2.52, 2.31‐2.76) | (0.46, 0.40‐0.53) | (0.37, 0.32‐0.43) | (0.61, 0.51‐0.72) | (0.52, 0.41‐0.67) | ||
| HRS Vs | 241 | 875 | 60 | 52 | 60 | 33 | 1,321 |
| (3.48, 3.01‐4.03) | (3.18, 2.83‐3.57) | (0.19, 0.14‐0.24) | (0.17, 0.13‐0.22) | (0.42, 0.33‐0.55) | (0.43, 0.30‐0.60) | ||
| IF Vs | 115 | 1.298 | 1.828 | 1.241 | 634 | 280 | 5,396 |
| (0.28, 0.23‐0.34) | (0.44, 0.41‐0.47) | (2.45, 2.30‐2.62) | (1.31, 1.22‐1.41) | (2.25, 1.15‐1.37) | (0.92, 0.81‐1.05) | ||
| HCoVs | 137 | 652 | 201 | 272 | 162 | 113 | 1,537 |
| (1.44, 1.20‐1.73) | (1.15, 1.04‐1.28) | (0.61, 0.52‐0.70) | (0.90, 0.79‐1.03) | (1.07, 0.91‐1.27) | (1.37, 1.12‐1.67) | ||
| HRV | 534 | 2.662 | 899 | 1.039 | 429 | 214 | 5,777 |
| (1.61, 1.46‐1.78) | (1.40, 1.33‐1.49) | (0.72, 0.66‐0.77) | (0.91, 0.85‐0.98) | (0.69, 0.62‐0.77) | (0.61, 0.53‐0.71) | ||
| HBoV | 141 | 536 | 28 | 10 | 3 | 0 | 718 |
| (3.69, 3.05‐4.46) | (4.72, 3.99‐5.59) | (0.16, 0.11‐0.24) | (0.06, 0.03‐0.11) | (0.04, 0.01‐0.12) | |||
| HMPV | 50 | 357 | 57 | 56 | 38 | 18 | 576 |
| (1.38, 1.03‐1.84) | (2.59, 2.19‐3.07) | (0.44, 0.34‐0.58) | (0.45, 0.34‐0.59) | (0.63, 0.46‐0.88) | (0.54, 0.34‐0.87) | ||
| Total | 1,647 (69.0) | 9,678 (67.0) | 3,672 (50.5) | 2,984 (42.1) | 1,502 (41.0) | 731 (35.7) | 20,214 |
a
Odds ratios were calculated based on the multivariate logistic regression for correlation of each virus and age groups.
b
The most frequently detected age group of each respiratory viruses.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.